Clinical Practice
Benzodiazepine Taper Protocol: 2026 PMHNP Guide
A benzodiazepine taper protocol for PMHNPs built on the 2025 joint guideline: 5-10% cuts every 2-4 weeks, when to pause, and how to get through the last steps.
Tagged
Controlled Substances
Real talk about psychopharmacology, clinical confidence, and building a practice you love — from Lindsay and the Fellowship faculty.
More Articles
Industry
Psychedelic Therapy in 2026: What PMHNPs Must Know
No psychedelic is FDA-approved yet, but two FDA notices in July 2026 moved the timeline. What PMHNPs need to know about psilocybin, MDMA, and state programs.
PMHNP Confidence
Saying No to Controlled Substances: A New PMHNP Confidence Script
A new PMHNP confidence script for declining inappropriate controlled substance requests — with exact language, rationale, and de-escalation frameworks.
Industry
DEA Telehealth Prescribing in 2026: What PMHNPs Must Know
DEA telehealth prescribing flexibilities expire December 31, 2026. Learn what PMHNPs need to know about controlled substance rules and how to prepare.
Career & Business
DEA Telehealth Prescribing Rules for 2026: What PMHNPs Running a Practice Need to Know
The DEA extended telehealth prescribing flexibilities for controlled substances through December 2026. Here's what PMHNPs building telehealth practices need to know before permanent rules arrive.